SAN ANTONIO -- Researchers have found new hope in
the battle against hepatitis C, the No. 1 cause of liver failure and liver
transplantation in the United States. Studies at the Southwest Foundation for
Biomedical Research offer the first evidence that a vaccine against all
strains of this elusive virus should be possible, since chimpanzees that have
previously cleared infection with one strain of the virus show protective
immunity to multiple strains.
While a vaccine could be years away, the finding is significant.
Scientists previously had thought that prior infection with hepatitis C virus
(HCV) only produced immunity to the specific strain with which one had been
infected, said lead investigator Dr. Robert E. Lanford of the Southwest
Foundation for Biomedical Research in San Antonio (SFBR). Lanford, his
colleagues at SFBR, and collaborators at the Johns Hopkins University School
of Medicine in Baltimore detail their discovery in an article published in the
Journal of Virology for its first edition for the month of February 2004.
Hepatitis C has six different genotypes, or highly divergent groups of
viruses, with numerous strains within each genotype. Researchers and
pharmaceutical companies have tried for years to develop an HCV vaccine,
focusing primarily on genotype 1, the most common genotype in the United
States and Europe. But there has been doubt that an HCV vaccine for one
genotype could be effective against others.
The discovery by Lanford's group that a potential vaccine against one
HCV strain could produce protective immunity to multiple strains was based on
research with chimpanzees at SFBR's Southwest National Primate Research Center
in San Antonio. Chimpanzees, initially developed by scientists at NIH and
SFBR as an animal model for HCV, are the only animals besides humans that can
be infected with the virus. As with humans, some chimpanzees maintain chronic
infections, while others manage to clear their infection; however, unlike
humans, chronically infected chimpanzees do not develop liver disease.
SFBR scientists found that chimpanzees that had cleared previous infection
with genotype 1 later showed protective immunity when rechallenged with
several different HCV strains. That was true even when the animals were
challenged with a highly complex mixture containing strains from genotypes 1,
2, 3 and 4 - the four major genotypes affecting most HCV victims around the
world.
Lanford explained that this finding has significant implications for
eventual development of an HCV vaccine "because it means when we are able to
make an effective vaccine and immunize a population, people should be
protected against all strains of hepatitis C to which they might be exposed."
In addition to being the No. 1 cause for cirrhosis of the liver, HCV
infects an estimated 3 percent of the world population, and accounts for
25 percent of all cases of liver cancer in the United States.
Source: Southwest Foundation for Biomedical Research
Dear Helpdesk: Working in a Toxic Health Care Environment
March 28th 2024Dear Helpdesk is your steadfast companion, offering life coaching and workplace advice from 2 seasoned IPs for some of your most challenging real-life situations. Let us help you navigate the intersection between work and life, guiding you to navigate the dynamic world of infection prevention with confidence and grace. This article is on handling a toxic health care environment.
Product Locator: Spring and Early Mother's Day Gift Guide for Infection Prevention Personnel
March 27th 2024Whether it's a spring holiday, birthdays, or no reason at all, infection prevention personnel love to give and receive gifts that help at the end of a stressful day. Infection Control Today® offers some gift ideas for infection prevention personnel and their families.
Catching Up With Vangie Dennis, AORN 2022-2023 President at AORN 2024
March 26th 2024Infection Control Today (ICT) had the privilege of catching up with Vangie Dennis, MSN, RN, CNOR, CMLSO, at the Association of periOperative Registered Nurses' (AORN’s) International Surgical Conference & Expo 2024. As the former president of AORN and an esteemed figure in perioperative services, Vangie Dennis shared insights into her recent endeavors and the exciting new chapter she's embarked upon.
How To Optimize Your Time Management Strategies for the Busy Infection Preventionist
March 25th 2024Is your calendar resembling a chaotic masterpiece of overlapping tasks? Join the club of infection preventionists striving to balance responsibilities. Dive into proven strategies from a fellow infection preventionist to reclaim control of your time, streamline tasks, and boost productivity effectively. This is an IP Lifeline article.